SLXN

Silexion is a clinical-stage Cayman holding company built out of a SPAC (Moringa) business combination with zero product revenue in its history (FY2023–FY2025 revenue all blank) and a cumulative deficit of -$55.2M. Its entire value rests on one asset, SIL204, a second-generation siRNA silencing mutated KRAS, which had not yet dosed a patient as of the filing — clinical studies were only 'expected in the second quarter of 2026, contingent upon obtaining regulatory clearance.' This is a binary, single-shot preclinical-to-clinical story, not a business with fundamentals to value.

The balance sheet cannot fund the plan. Management states outright: 'there is substantial doubt about our ability to continue as a going concern,' and that the $6.0M cash on hand is 'sufficient to fund business operations for only several months from the filing date.' With operating cash flow of -$10.8M in FY2025 and R&D rising 22.8% to $7.14M as trials ramp, the burn exceeds the cash. The stated fix is more dilution — 'public and private equity offerings,' warrant-exercise inducements, and ATM sales — and the share count already tells that story: shares outstanding of 3.33B alongside a history of reverse splits and 2025 HCW offerings. Existing holders face near-certain, heavy dilution simply to keep the lights on.